{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:22:58Z","timestamp":1793380978585,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Decreased cytomegalovirus (CMV)-specific immunity after hematopoietic cell transplantation (HCT) is associated with late CMV reactivation and increased mortality. Whether letermovir prophylaxis-associated reduction in viral exposure influences CMV-specific immune reconstitution is unknown. In a prospective cohort of allogeneic HCT recipients who received letermovir, we compared polyfunctional CMV-specific T-cell responses to those of controls who received PCR-guided preemptive therapy before the introduction of letermovir. Thirteen-color flow cytometry was used to assess T-cell responses at 3 months after HCT following stimulation with CMV immediate early-1 (IE-1) antigen and phosphoprotein 65 (pp65) antigens. Polyfunctionality was characterized by combinatorial polyfunctionality analysis of antigen-specific T-cell subsets. Use of letermovir and reduction of viral exposure were assessed for their association with CMV-specific T-cell immunity. Polyfunctional T-cell responses to IE-1 and pp65 were decreased in letermovir recipients and remained diminished after adjustment for donor CMV serostatus, absolute lymphocyte count, and steroid use. Among letermovir recipients, greater peak CMV DNAemia and increased viral shedding were associated with stronger CD8+ responses to pp65, whereas the CMV shedding rate was associated with greater CD4+ responses to IE-1. In summary, our study provided initial evidence that letermovir may delay CMV-specific cellular reconstitution, possibly related to decreased CMV antigen exposure. Evaluating T-cell polyfunctionality may identify patients at risk for late CMV infection after HCT.<\/jats:p>","DOI":"10.1182\/blood.2020009396","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T21:34:01Z","timestamp":1614807241000},"page":"34-43","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":173,"title":["Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation"],"prefix":"10.1182","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-2902","authenticated-orcid":false,"given":"Danniel","family":"Zamora","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-9039","authenticated-orcid":false,"given":"Elizabeth R.","family":"Duke","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Xie","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C.","family":"Edmison","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Akoto","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kiener","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Stevens-Ayers","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany;"},{"name":"Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-8688","authenticated-orcid":false,"given":"Marco","family":"Mielcarek","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Medical Oncology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0906","authenticated-orcid":false,"given":"Wendy M.","family":"Leisenring","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Jerome","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2598-1621","authenticated-orcid":false,"given":"Joshua T.","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4341-9090","authenticated-orcid":false,"given":"Greg","family":"Finak","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1538-7984","authenticated-orcid":false,"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"issue":"25","key":"2021070815252937600_B1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylasix for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"2021070815252937600_B2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/ajt.15764","article-title":"Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation","volume":"20","author":"Marty","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"2021070815252937600_B3","doi-asserted-by":"crossref","first-page":"e133960","DOI":"10.1172\/JCI133960","article-title":"CMV viral load kinetics as surrogate endpoints after allogeneic transplantation","volume":"131","author":"Duke","year":"2021","journal-title":"J Clin Invest"},{"issue":"2","key":"2021070815252937600_B4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2002-03-0993","article-title":"Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity","volume":"101","author":"Boeckh","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2021070815252937600_B5","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1182\/blood-2002-11-3472","article-title":"Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation","volume":"102","author":"Hakki","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2021070815252937600_B6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3324\/haematol.11912","article-title":"Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection","volume":"93","author":"Lilleri","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2021070815252937600_B7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bbmt.2014.01.018","article-title":"Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation","volume":"20","author":"Lugthart","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2021070815252937600_B8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3324\/haematol.2014.113415","article-title":"Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation","volume":"100","author":"Itzykson","year":"2015","journal-title":"Haematologica"},{"issue":"25","key":"2021070815252937600_B9","doi-asserted-by":"crossref","first-page":"6465","DOI":"10.1182\/blood-2009-02-203307","article-title":"Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients","volume":"113","author":"Zhou","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2021070815252937600_B10","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V83.7.1971.1971","article-title":"Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis","volume":"83","author":"Li","year":"1994","journal-title":"Blood"},{"issue":"11","key":"2021070815252937600_B11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/sj.bmt.1700801","article-title":"Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease","volume":"19","author":"Krause","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2021070815252937600_B12","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2018-10-878918","article-title":"Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation","volume":"133","author":"Camargo","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2021070815252937600_B13","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"Lin","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2021070815252937600_B14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/infdis\/jiaa422","article-title":"Donor-derived CD4+ T cells and HHV-6B reactivation after allogeneic hematopoietic cell transplantation","volume":"223","author":"Hanson","year":"2021","journal-title":"J Infect Dis"},{"issue":"5","key":"2021070815252937600_B15","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/cid\/ciw370","article-title":"Are we there yet? Impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples","volume":"63","author":"Preiksaitis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021070815252937600_B16","article-title":"Time CMV Assay [package insert]","author":"Real","year":"2017"},{"issue":"1","key":"2021070815252937600_B17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2021070815252937600_B18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiz181","article-title":"Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive\/recipient-seronegative liver transplant recipients receiving either preemptive therapy or antiviral prophylaxis","volume":"220","author":"Limaye","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"2021070815252937600_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann Intern Med"},{"issue":"14","key":"2021070815252937600_B20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1001\/jama.2020.3138","article-title":"Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial","volume":"323","author":"Singh","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"2021070815252937600_B21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"issue":"9","key":"2021070815252937600_B22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jix086","article-title":"Higher T-cell responses induced by DNA\/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial","volume":"215","author":"Janes","year":"2017","journal-title":"J Infect Dis"},{"issue":"6","key":"2021070815252937600_B23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1084\/jem.20062363","article-title":"Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses","volume":"204","author":"Precopio","year":"2007","journal-title":"J Exp Med"},{"issue":"8","key":"2021070815252937600_B24","doi-asserted-by":"crossref","first-page":"e106044","DOI":"10.1371\/journal.pone.0106044","article-title":"Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients","volume":"9","author":"Gabanti","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2021070815252937600_B25","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"2021070815252937600_B26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.immunol.26.021607.090404","article-title":"Death by a thousand cuts: granzyme pathways of programmed cell death","volume":"26","author":"Chowdhury","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"2021070815252937600_B27","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/infdis\/156.6.899","article-title":"Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses","volume":"156","author":"Bowden","year":"1987","journal-title":"J Infect Dis"},{"issue":"6","key":"2021070815252937600_B28","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1172\/JCI115217","article-title":"Inhibition of immune functions by antiviral drugs","volume":"87","author":"Heagy","year":"1991","journal-title":"J Clin Invest"},{"issue":"7","key":"2021070815252937600_B29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2007.03.009","article-title":"Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis","volume":"13","author":"Battiwalla","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021070815252937600_B30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcv.2015.12.012","article-title":"In vitro studies of the impact of maribavir on CMV-specific cellular immune responses","volume":"75","author":"Stachel","year":"2016","journal-title":"J Clin Virol"},{"issue":"3","key":"2021070815252937600_B31","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"20","key":"2021070815252937600_B32","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"issue":"8","key":"2021070815252937600_B33","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.4049\/jimmunol.146.8.2795","article-title":"Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression","volume":"146","author":"Riddell","year":"1991","journal-title":"J Immunol"},{"issue":"2","key":"2021070815252937600_B34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/AAC.25.2.247","article-title":"Effects of the nucleoside analog 2\u2032-nor-2\u2032-deoxyguanosine on human cytomegalovirus replication","volume":"25","author":"Tocci","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2021070815252937600_B35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dof.2013.038.05.1946425","article-title":"Letermovir treatment of human cytomegalovirus infection antiinfective agent","volume":"38","author":"Verghese","year":"2013","journal-title":"Drugs Future"},{"issue":"7","key":"2021070815252937600_B36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20042384","article-title":"Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells","volume":"201","author":"Bunde","year":"2005","journal-title":"J Exp Med"},{"issue":"4","key":"2021070815252937600_B37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cyto.b.20420","article-title":"Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations","volume":"74","author":"Gratama","year":"2008","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/1\/34\/1812988\/bloodbld2020009396.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/138\/1\/34\/1812988\/bloodbld2020009396.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T10:29:11Z","timestamp":1697970551000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/1\/34\/475413\/Cytomegalovirus-specific-T-cell-reconstitution"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,3]]},"published-print":{"date-parts":[[2021,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009396","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]}}}